Geron Corp
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is GERN moving today?
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
GERN overview
Related filings and maps
Congress activity in GERN
No receipt-qualified Congressional disclosure is present for GERN in the cached public ledger.
GERN contract awards, year to date.
Public federal awards linked to this ticker.
GERN lobbying filings, year to date.
Registered lobbying filings matched to Geron Corp.
MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP)
MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP)
MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP)